CAR-T（CAR-T）细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
通过微环 DNA 快速生成 CD19 CAR-T 细胞实现抗肿瘤活性并预防致死性 CAR-B 白血病
英文原题：Rapid generation of CD19 CAR-T cells by minicircle DNA enables anti-tumor activity and prevents fatal CAR-B leukemia.
查看英文原题
Rapid generation of CD19 CAR-T cells by minicircle DNA enables anti-tumor activity and prevents fatal CAR-B leukemia.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
使用病毒载体制造嵌合抗原受体（CAR）T细胞成本高且耗时长。此外，病毒转导过程中，CAR编码基因会随机整合至基因组，可能导致致癌或产生危险的CAR肿瘤细胞。本研究采用无病毒、非转基因的小环DNA（mcDNA）载体，在两天内快速制备CD19 CAR-T 细胞。研究进一步在体外和异种移植模型中证明，mcDNA制备的CD19 CAR-T 细胞抗肿瘤作用与病毒载体制备的细胞同样有效。最后，研究显示该制造流程可避免产生致命的CAR肿瘤细胞。综上，研究提供了一种快速、有效且具有治疗安全性的CD19 CAR-T 细胞制备方法，可用于治疗白血病。
展开英文摘要原文
Manufacturing chimeric antigen receptor (CAR)-T cells using viral vectors is expensive and time-consuming.
In addition, during viral transduction, genes encoding CARs are randomly integrated into the genome, which can cause oncogenesis or produce devastating CAR-tumor cells.
Here, using a virus-free and non-transgenic minicircle DNA (mcDNA) vector, we enabled the rapid generation of CD19 CAR-T cells within two days.
Furthermore, we demonstrated in vitro and in xenograft models that the antitumor effects of CD19 CAR-T cells produced by mcDNA are as effective as those produced by viral vectors.
Finally, we showed that our manufacturing process avoids the production of fatal CAR-tumor cells. Taken together, we have provided a fast, effective, and therapeutically safe method for generating CD19 CAR-T cells for the treatment of leukemia.
论文信息
- 作者
- Ye X、Wu Y、Zhang H、Shi L、Zhou Y、Guo S、Dong J、Cai J
- 第一作者单位
- Department of Surgery, Hebei Medical University, 361 East Zhongshan Road, Shijiazhuang, 050017, China; Department of Oncology & Surgery, Hebei General Hospital, 348 West Heping Road, Shijiazhuang, 050051, China; R&D Center, Yetem Biotech Hebei Corp. Ltd., Zhengding-Area of Hebei Free-Trade Zone, Shijiazhuang, 050899, China. Electronic address: xueshuaiye1992@126.com.China
- 通讯作者单位
- Department of Surgery, Hebei Medical University, 361 East Zhongshan Road, Shijiazhuang, 050017, China; Department of Oncology & Surgery, Hebei General Hospital, 348 West Heping Road, Shijiazhuang, 050051, China; R&D Center, Yetem Biotech Hebei Corp. Ltd., Zhengding-Area of Hebei Free-Trade Zone, Shijiazhuang, 050899, China. Electronic address: jianhuicai2001@163.com.China
- 文献类型
- 非美国政府资助研究
- 期刊
- Cancer letters2023 Aug 1
- 原文标识
- PubMed 37354981 · DOI 10.1016/j.canlet.2023.216278